Theravance Biopharma Stock Forward View
| TBPH Stock | USD 19.53 0.13 0.67% |
Theravance Stock outlook is based on your current time horizon. We suggest always using this module together with an analysis of Theravance Biopharma's historical fundamentals, such as revenue growth or operating cash flow patterns.
As of 16th of February 2026 the relative strength index (rsi) of Theravance Biopharma's share price is below 20 . This usually implies that the stock is significantly oversold. The fundamental principle of the Relative Strength Index (RSI) is to quantify the velocity at which market participants are driving the price of a financial instrument upwards or downwards. Momentum 0
Sell Peaked
Oversold | Overbought |
EPS Estimate Next Quarter 0.15 | EPS Estimate Current Year 0.12 | EPS Estimate Next Year 1.69 | Wall Street Target Price 26.7143 | EPS Estimate Current Quarter (0.05) |
Using Theravance Biopharma hype-based prediction, you can estimate the value of Theravance Biopharma from the perspective of Theravance Biopharma response to recently generated media hype and the effects of current headlines on its competitors. We also analyze overall investor sentiment towards Theravance Biopharma using Theravance Biopharma's stock options and short interest. It helps to benchmark the overall future attitude of investors towards Theravance using crowd psychology based on the activity and movement of Theravance Biopharma's stock price.
Theravance Biopharma Implied Volatility | 2.51 |
Theravance Biopharma's implied volatility exposes the market's sentiment of Theravance Biopharma stock's possible movements over time. However, it does not forecast the overall direction of its price. In a nutshell, if Theravance Biopharma's implied volatility is high, the market thinks the stock has potential for high price swings in either direction. On the other hand, the low implied volatility suggests that Theravance Biopharma stock will not fluctuate a lot when Theravance Biopharma's options are near their expiration.
The Naive Prediction forecasted value of Theravance Biopharma on the next trading day is expected to be 20.04 with a mean absolute deviation of 0.40 and the sum of the absolute errors of 24.61. Theravance Biopharma after-hype prediction price | USD 19.53 |
There is no one specific way to measure market sentiment using hype analysis or a similar predictive technique. This prediction method should be used in combination with more fundamental and traditional techniques such as stock price forecasting, technical analysis, analysts consensus, earnings estimates, and various momentum models.
Theravance | Build AI portfolio with Theravance Stock |
Prediction based on Rule 16 of the current Theravance contract
Based on the Rule 16, the options market is currently suggesting that Theravance Biopharma will have an average daily up or down price movement of about 0.16% per day over the life of the 2026-03-20 option contract. With Theravance Biopharma trading at USD 19.53, that is roughly USD 0.0306 . If you think that the market is fully incorporating Theravance Biopharma's daily price movement you should consider acquiring Theravance Biopharma options at the current volatility level of 2.51%. But if you have an opposite viewpoint you should avoid it and even consider selling them.
Open Interest Against 2026-03-20 Theravance Option Contracts
Although open interest is a measure utilized in the options markets, it could be used to forecast Theravance Biopharma's spot prices because the number of available contracts in the market changes daily, and new contracts can be created or liquidated at will. Since open interest in Theravance Biopharma's options reflects these daily shifts, investors could use the patterns of these changes to develop long and short-term trading strategies for Theravance Biopharma stock based on available contracts left at the end of a trading day.
Please note that to derive more accurate forecasting about market movement from the current Theravance Biopharma's open interest, investors have to compare it to Theravance Biopharma's spot prices. As Ford's stock price increases, high open interest indicates that money is entering the market, and the market is strongly bullish. Conversely, if the price of Theravance Biopharma is decreasing and there is high open interest, that is a sign that the bearish trend will continue, and investors may react by taking short positions in Theravance. So, decreasing or low open interest during a bull market indicates that investors are becoming uncertain of the depth of the bullish trend, and a reversal in sentiment will likely follow.
Theravance Biopharma Additional Predictive Modules
Most predictive techniques to examine Theravance price help traders to determine how to time the market. We provide a combination of tools to recognize potential entry and exit points for Theravance using various technical indicators. When you analyze Theravance charts, please remember that the event formation may indicate an entry point for a short seller, and look at other indicators across different periods to confirm that a breakdown or reversion is likely to occur.| Cycle Indicators | ||
| Math Operators | ||
| Math Transform | ||
| Momentum Indicators | ||
| Overlap Studies | ||
| Pattern Recognition | ||
| Price Transform | ||
| Statistic Functions | ||
| Volatility Indicators | ||
| Volume Indicators |
Theravance Biopharma Cash Forecast
Predicting cash flow or other financial metrics requires analysts to utilize a variety of statistical methods, techniques, and algorithms. These tools help uncover hidden patterns in the Theravance Biopharma's financial statements, enabling forecasts of their impact on future stock prices.
Cash | First Reported 2013-12-31 | Previous Quarter 281.9 M | Current Value 174.8 M | Quarterly Volatility 93.7 M |
Theravance Biopharma Naive Prediction Price Forecast For the 17th of February 2026
Given 90 days horizon, the Naive Prediction forecasted value of Theravance Biopharma on the next trading day is expected to be 20.04 with a mean absolute deviation of 0.40, mean absolute percentage error of 0.25, and the sum of the absolute errors of 24.61.Please note that although there have been many attempts to predict Theravance Stock prices using its time series forecasting, we generally do not suggest using it to place bets in the real market. The most commonly used models for forecasting predictions are the autoregressive models, which specify that Theravance Biopharma's next future price depends linearly on its previous prices and some stochastic term (i.e., imperfectly predictable multiplier).
Theravance Biopharma Stock Forecast Pattern
| Backtest Theravance Biopharma | Theravance Biopharma Price Prediction | Research Analysis |
Theravance Biopharma Forecasted Value
In the context of forecasting Theravance Biopharma's Stock value on the next trading day, we examine the predictive performance of the model to find good statistically significant boundaries of downside and upside scenarios. Theravance Biopharma's downside and upside margins for the forecasting period are 17.68 and 22.40, respectively. We have considered Theravance Biopharma's daily market price to evaluate the above model's predictive performance. Remember, however, there is no scientific proof or empirical evidence that traditional linear or nonlinear forecasting models outperform artificial intelligence and frequency domain models to provide accurate forecasts consistently.
Model Predictive Factors
The below table displays some essential indicators generated by the model showing the Naive Prediction forecasting method's relative quality and the estimations of the prediction error of Theravance Biopharma stock data series using in forecasting. Note that when a statistical model is used to represent Theravance Biopharma stock, the representation will rarely be exact; so some information will be lost using the model to explain the process. AIC estimates the relative amount of information lost by a given model: the less information a model loses, the higher its quality.| AIC | Akaike Information Criteria | 116.7344 |
| Bias | Arithmetic mean of the errors | None |
| MAD | Mean absolute deviation | 0.4035 |
| MAPE | Mean absolute percentage error | 0.0212 |
| SAE | Sum of the absolute errors | 24.6138 |
Predictive Modules for Theravance Biopharma
There are currently many different techniques concerning forecasting the market as a whole, as well as predicting future values of individual securities such as Theravance Biopharma. Regardless of method or technology, however, to accurately forecast the stock market is more a matter of luck rather than a particular technique. Nevertheless, trying to predict the stock market accurately is still an essential part of the overall investment decision process. Using different forecasting techniques and comparing the results might improve your chances of accuracy even though unexpected events may often change the market sentiment and impact your forecasting results.Theravance Biopharma After-Hype Price Density Analysis
As far as predicting the price of Theravance Biopharma at your current risk attitude, this probability distribution graph shows the chance that the prediction will fall between or within a specific range. We use this chart to confirm that your returns on investing in Theravance Biopharma or, for that matter, your successful expectations of its future price, cannot be replicated consistently. Please note, a large amount of money has been lost over the years by many investors who confused the symmetrical distributions of Stock prices, such as prices of Theravance Biopharma, with the unreliable approximations that try to describe financial returns.
Next price density |
| Expected price to next headline |
Theravance Biopharma Estimiated After-Hype Price Volatility
In the context of predicting Theravance Biopharma's stock value on the day after the next significant headline, we show statistically significant boundaries of downside and upside scenarios based on Theravance Biopharma's historical news coverage. Theravance Biopharma's after-hype downside and upside margins for the prediction period are 17.17 and 21.89, respectively. We have considered Theravance Biopharma's daily market price in relation to the headlines to evaluate this method's predictive performance. Remember, however, there is no scientific proof or empirical evidence that news-based prediction models compare with traditional linear, nonlinear models or artificial intelligence models to provide accurate predictions consistently.
Current Value
Theravance Biopharma is very steady at this time. Analysis and calculation of next after-hype price of Theravance Biopharma is based on 3 months time horizon.
Theravance Biopharma Stock Price Outlook Analysis
Have you ever been surprised when a price of a Company such as Theravance Biopharma is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Theravance Biopharma backward and forwards among themselves. Have you ever observed a lot of a particular company's price movement is driven by press releases or news about the company that has nothing to do with actual earnings? Usually, hype to individual companies acts as price momentum. If not enough favorable publicity is forthcoming, the Stock price eventually runs out of speed. So, the rule of thumb here is that as long as this news hype has nothing to do with immediate earnings, you should pay more attention to it. If you see this tendency with Theravance Biopharma, there might be something going there, and it might present an excellent short sale opportunity.
| Expected Return | Period Volatility | Hype Elasticity | Related Elasticity | News Density | Related Density | Expected Hype |
0.12 | 2.36 | 0.00 | 0.02 | 25 Events / Month | 7 Events / Month | In about 25 days |
| Latest traded price | Expected after-news price | Potential return on next major news | Average after-hype volatility | |
19.53 | 19.53 | 0.00 |
|
Theravance Biopharma Hype Timeline
Theravance Biopharma is at this time traded for 19.53. The entity stock is not elastic to its hype. The average elasticity to hype of competition is 0.02. Theravance is projected not to react to the next headline, with the price staying at about the same level, and average media hype impact volatility is over 100%. The immediate return on the next news is projected to be very small, whereas the daily expected return is at this time at 0.12%. %. The volatility of related hype on Theravance Biopharma is about 1774.44%, with the expected price after the next announcement by competition of 19.55. About 99.0% of the company shares are owned by institutional investors. The book value of Theravance Biopharma was at this time reported as 4.59. The company had not issued any dividends in recent years. Given the investment horizon of 90 days the next projected press release will be in about 25 days. Check out Historical Fundamental Analysis of Theravance Biopharma to cross-verify your projections.Theravance Biopharma Related Hype Analysis
Having access to credible news sources related to Theravance Biopharma's direct competition is more important than ever and may enhance your ability to predict Theravance Biopharma's future price movements. Getting to know how Theravance Biopharma's peers react to changing market sentiment, related social signals, and mainstream news is a great way to find investing opportunities and time the market. The summary table below summarizes the essential lagging indicators that can help you analyze how Theravance Biopharma may potentially react to the hype associated with one of its peers.
| HypeElasticity | NewsDensity | SemiDeviation | InformationRatio | PotentialUpside | ValueAt Risk | MaximumDrawdown | |||
| BTX | BlackRock Technology and | (0.13) | 6 per month | 0.00 | (0.10) | 2.50 | (2.42) | 6.61 | |
| GLUE | Monte Rosa Therapeutics | (0.86) | 9 per month | 3.75 | 0.07 | 10.83 | (6.69) | 53.94 | |
| DAWN | Day One Biopharmaceuticals | 2.26 | 9 per month | 3.96 | 0.04 | 11.23 | (6.53) | 33.27 | |
| GERN | Geron | 0.04 | 9 per month | 2.57 | 0.15 | 6.72 | (3.70) | 16.99 | |
| REPL | Replimune Group | (0.38) | 7 per month | 0.00 | (0.04) | 5.56 | (5.32) | 14.00 | |
| VIR | Vir Biotechnology | 0.03 | 10 per month | 3.33 | 0.12 | 8.08 | (5.45) | 23.40 | |
| LENZ | LENZ Therapeutics | (1.11) | 7 per month | 0.00 | (0.14) | 8.05 | (6.56) | 40.02 | |
| AVBP | ArriVent BioPharma Common | 0.35 | 3 per month | 2.91 | 0.08 | 6.71 | (4.81) | 18.12 | |
| VALN | Valneva SE ADR | (0.07) | 3 per month | 2.33 | 0.05 | 5.40 | (4.81) | 15.59 | |
| TYRA | Tyra Biosciences | 1.20 | 8 per month | 2.01 | 0.22 | 6.05 | (4.26) | 34.11 |
Other Forecasting Options for Theravance Biopharma
For every potential investor in Theravance, whether a beginner or expert, Theravance Biopharma's price movement is the inherent factor that sparks whether it is viable to invest in it or hold it better. Theravance Stock price charts are filled with many 'noises.' These noises can hugely alter the decision one can make regarding investing in Theravance. Basic forecasting techniques help filter out the noise by identifying Theravance Biopharma's price trends.Theravance Biopharma Related Equities
One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with Theravance Biopharma stock to make a market-neutral strategy. Peer analysis of Theravance Biopharma could also be used in its relative valuation, which is a method of valuing Theravance Biopharma by comparing valuation metrics with similar companies.
| Risk & Return | Correlation |
Theravance Biopharma Market Strength Events
Market strength indicators help investors to evaluate how Theravance Biopharma stock reacts to ongoing and evolving market conditions. The investors can use it to make informed decisions about market timing, and determine when trading Theravance Biopharma shares will generate the highest return on investment. By undertsting and applying Theravance Biopharma stock market strength indicators, traders can identify Theravance Biopharma entry and exit signals to maximize returns.
Theravance Biopharma Risk Indicators
The analysis of Theravance Biopharma's basic risk indicators is one of the essential steps in accurately forecasting its future price. The process involves identifying the amount of risk involved in Theravance Biopharma's investment and either accepting that risk or mitigating it. Along with some essential techniques for forecasting theravance stock prices, we also provide a set of basic risk indicators that can assist in the individual investment decision or help in hedging the risk of your existing portfolios.
| Mean Deviation | 2.23 | |||
| Semi Deviation | 2.27 | |||
| Standard Deviation | 3.68 | |||
| Variance | 13.55 | |||
| Downside Variance | 6.86 | |||
| Semi Variance | 5.16 | |||
| Expected Short fall | (2.41) |
Please note, the risk measures we provide can be used independently or collectively to perform a risk assessment. When comparing two potential investments, we recommend comparing similar equities with homogenous growth potential and valuation from related markets to determine which investment holds the most risk.
Story Coverage note for Theravance Biopharma
The number of cover stories for Theravance Biopharma depends on current market conditions and Theravance Biopharma's risk-adjusted performance over time. The coverage that generates the most noise at a given time depends on the prevailing investment theme that Theravance Biopharma is classified under. However, while its typical story may have numerous social followers, the rapid visibility can also attract short-sellers, who usually are skeptical about Theravance Biopharma's long-term prospects. So, having above-average coverage will typically attract above-average short interest, leading to significant price volatility.
Contributor Headline
Latest Perspective From Macroaxis
Theravance Biopharma Short Properties
Theravance Biopharma's future price predictability will typically decrease when Theravance Biopharma's long traders begin to feel the short-sellers pressure to drive the price lower. The predictive aspect of Theravance Biopharma often depends not only on the future outlook of the potential Theravance Biopharma's investors but also on the ongoing dynamics between investors with different trading styles. Because the market risk indicators may have small false signals, it is better to identify suitable times to hedge a portfolio using different long/short signals. Theravance Biopharma's indicators that are reflective of the short sentiment are summarized in the table below.
| Common Stock Shares Outstanding | 48.8 M | |
| Cash And Short Term Investments | 88.3 M |
Check out Historical Fundamental Analysis of Theravance Biopharma to cross-verify your projections. For more detail on how to invest in Theravance Stock please use our How to Invest in Theravance Biopharma guide.You can also try the Portfolio Holdings module to check your current holdings and cash postion to detemine if your portfolio needs rebalancing.
Is there potential for Pharmaceuticals market expansion? Will Theravance introduce new products? Factors like these will boost the valuation of Theravance Biopharma. If investors know Theravance will grow in the future, the company's valuation will be higher. Understanding fair value requires weighing current performance against future potential. All the valuation information about Theravance Biopharma listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share 0.57 | Revenue Per Share | Quarterly Revenue Growth 0.185 | Return On Assets | Return On Equity |
The market value of Theravance Biopharma is measured differently than its book value, which is the value of Theravance that is recorded on the company's balance sheet. Investors also form their own opinion of Theravance Biopharma's value that differs from its market value or its book value, called intrinsic value, which is Theravance Biopharma's true underlying value. Analysts utilize numerous techniques to assess fundamental value, seeking to purchase shares when trading prices fall beneath estimated intrinsic worth. Because Theravance Biopharma's market value can be influenced by many factors that don't directly affect Theravance Biopharma's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Theravance Biopharma's value and its price as these two are different measures arrived at by different means. Investors typically determine if Theravance Biopharma is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. Meanwhile, Theravance Biopharma's quoted price indicates the marketplace figure where supply meets demand through bilateral consent.